US FDA approves Acer’s olpruva to treat urea cycle disorders

Olpruva is indicated to treat UCDs patients with carbamylphosphate synthetase, ornithine transcarbamylase or argininosuccinic acid synthetase deficiencies. Credit: Michał Parzuchowski on Unsplash.